ARKG ETF Profile

Family:	ARK Funds
Name:	ARK Genomic Revolution ETF

Inception Date:	31-Oct-2014
Termination Date:
Investment Objective:	ARKG is an actively managed Exchange Traded Fund (ETF) that seeks long-term growth of capital by investing under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including health care, information technology, materials, energy, and consumer discretionary, that are relevant to the Fund's investment theme of the genomics revolution. Companies within ARKG are focused on and are expected to substantially benefit from extending and enhancing the quality of human and other life by incorporating technological and scientific developments and advancements in genomics into their business. ARKG will be concentrated in issuers in any industry or group of industries in the health care sector, including issuers having their principal business activities in the biotechnology industry. The companies held in ARKG may be leaders, enablers, or beneficiaries of technologies.

Prospectus

Top 10 Holdings
CRISPR THERAPEUTICS AG	CRSP	7.3900%
TWIST BIOSCIENCE CORP	TWST	6.1000%
EXACT SCIENCES CORP	EXAS	5.5800%
RECURSION PHARMACEUTICALS-A	RXRX	5.1500%
SCHRODINGER INC	SDGR	4.6300%
IONIS PHARMACEUTICALS INC	IONS	4.3200%
BEAM THERAPEUTICS INC	BEAM	3.9500%
ACCOLADE INC	ACCD	3.8900%
INTELLIA THERAPEUTICS INC	NTLA	3.8800%
GINKGO BIOWORKS HOLDINGS INC	DNA	3.7000%
	Top 10 Holdings Weight:	48.6%